In new research published in the Journal of Clinical Investigation, a team at the Institute of Cancer Research, London, ...

Bio-Path (BPTH) provided an update from the company’s ongoing Phase 1/1b clinical trial evaluating BP1002 for the treatment of ...

Patients treated in community settings were more likely to be older, less likely to be White, and had worse survival rates, ...

Venetoclax, a selective Bcl-2 inhibitor, has proven effective in chronic lymphocytic leukemia (CLL), but genetic mutations or ...